These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 22307178)
1. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Westers TM; Ireland R; Kern W; Alhan C; Balleisen JS; Bettelheim P; Burbury K; Cullen M; Cutler JA; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Johansson U; Kordasti S; Loken MR; Malcovati L; te Marvelde JG; Matarraz S; Milne T; Moshaver B; Mufti GJ; Ogata K; Orfao A; Porwit A; Psarra K; Richards SJ; Subirá D; Tindell V; Vallespi T; Valent P; van der Velden VH; de Witte TM; Wells DA; Zettl F; Béné MC; van de Loosdrecht AA Leukemia; 2012 Jul; 26(7):1730-41. PubMed ID: 22307178 [TBL] [Abstract][Full Text] [Related]
2. Cutting edge: flow cytometry in myelodysplastic syndromes. van de Loosdrecht AA; Westers TM J Natl Compr Canc Netw; 2013 Jul; 11(7):892-902. PubMed ID: 23847222 [TBL] [Abstract][Full Text] [Related]
3. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. van de Loosdrecht AA; Ireland R; Kern W; Della Porta MG; Alhan C; Balleisen JS; Bettelheim P; Bowen DT; Burbury K; Eidenschink L; Cazzola M; Chu SS; Cullen M; Cutler JA; Dräger AM; Feuillard J; Fenaux P; Font P; Germing U; Haase D; Hellström-Lindberg E; Johansson U; Kordasti S; Loken MR; Malcovati L; te Marvelde JG; Matarraz S; Milne T; Moshaver B; Mufti GJ; Nikolova V; Ogata K; Oelschlaegel U; Orfao A; Ossenkoppele GJ; Porwit A; Platzbecker U; Preijers F; Psarra K; Richards SJ; Subirá D; Seymour JF; Tindell V; Vallespi T; Valent P; van der Velden VH; Wells DA; de Witte TM; Zettl F; Béné MC; Westers TM Leuk Lymphoma; 2013 Mar; 54(3):472-5. PubMed ID: 22916713 [TBL] [Abstract][Full Text] [Related]
4. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS. Westers TM; van der Velden VH; Alhan C; Bekkema R; Bijkerk A; Brooimans RA; Cali C; Dräger AM; de Haas V; Homburg C; de Jong A; Kuiper-Kramer PE; Leenders M; Lommerse I; te Marvelde JG; van der Molen-Sinke JK; Moshaver B; Mulder AB; Preijers FW; Schindhelm RK; van der Sluijs A; van Wering ER; Westra AH; van de Loosdrecht AA; Leuk Res; 2012 Apr; 36(4):422-30. PubMed ID: 21982641 [TBL] [Abstract][Full Text] [Related]
5. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. van de Loosdrecht AA; Alhan C; Béné MC; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Homburg CH; Ireland R; Jansen JH; Kern W; Malcovati L; Te Marvelde JG; Mufti GJ; Ogata K; Orfao A; Ossenkoppele GJ; Porwit A; Preijers FW; Richards SJ; Schuurhuis GJ; Subirá D; Valent P; van der Velden VH; Vyas P; Westra AH; de Witte TM; Wells DA; Loken MR; Westers TM Haematologica; 2009 Aug; 94(8):1124-34. PubMed ID: 19546437 [TBL] [Abstract][Full Text] [Related]
6. Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. Della Porta MG; Lanza F; Del Vecchio L; Cytometry B Clin Cytom; 2011; 80(4):201-11. PubMed ID: 21674774 [TBL] [Abstract][Full Text] [Related]
7. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943 [TBL] [Abstract][Full Text] [Related]
8. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G; J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153 [TBL] [Abstract][Full Text] [Related]
9. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170 [TBL] [Abstract][Full Text] [Related]
10. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances]. Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725 [TBL] [Abstract][Full Text] [Related]
11. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954 [TBL] [Abstract][Full Text] [Related]
12. Role of flow cytometry in myelodysplastic syndromes: diagnosis, classification, prognosis and response assessment. Burbury KL; Westerman DA Leuk Lymphoma; 2014 Apr; 55(4):749-60. PubMed ID: 23808833 [TBL] [Abstract][Full Text] [Related]
13. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of myelodysplastic syndromes in cytopenic patients. Wang SA Hematol Oncol Clin North Am; 2011 Oct; 25(5):1085-110, vii. PubMed ID: 22054736 [TBL] [Abstract][Full Text] [Related]
15. Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations. Alhan C; Westers TM; Cremers EM; Cali C; Ossenkoppele GJ; van de Loosdrecht AA Cytometry B Clin Cytom; 2016 Jul; 90(4):358-67. PubMed ID: 26517178 [TBL] [Abstract][Full Text] [Related]
16. [Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome]. Lu D; Liu YR Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):785-90. PubMed ID: 23815941 [TBL] [Abstract][Full Text] [Related]
18. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Xu F; Li X; Wu L; He Q; Zhang Z; Chang C Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463 [TBL] [Abstract][Full Text] [Related]
19. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Orazi A Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881 [TBL] [Abstract][Full Text] [Related]
20. [Classification and clinical findings of myelodysplastic syndromes]. Tsuruda K; Hasegawa H; Fuchigami M; Uno N; Morinaga Y; Miyazaki Y; Yanagihara K Rinsho Byori; 2014 Apr; 62(4):359-68. PubMed ID: 25022065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]